Listing of th Claim :

The following listing of claims replaces all prior versions, and listings, of claims in the application:

Claims 1-14 (canceled)

Claim 15 (currently amended): A medicament for use in the treatment of a human patient diagnosed with dementia comprising a therapeutic unit of Colostrinin in isolated form for [~~use in the treatment of dementia in humans~~] oral administration to the human patient.

Claim16 (currently amended): A medicament for use in the treatment of a human patient diagnosed with Alzheimer's disease comprising a therapeutic unit of Colostrinin in isolated form for [~~use in the treatment of Alzheimer's disease in humans~~] oral administration to the human patient.

Claims 17-23 (canceled)

Claim 24 (previously presented): A method of treating a human patient afflicted with dementia comprising administering a composition comprising a therapeutic unit of Colostrinin in isolated form to the human patient about one or two times per day for a predetermined period of time.

Claim 25 (canceled)

Claim 26 (previously presented): The method according to claim 24 wherein the Colostrinin is non-ovine Colostrinin.

Claim 27 (previously presented): The method according to claim 24, wherein the therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms.

Claim 28 (previously presented): The method according to claim 24 wherein the therapeutic unit of Colostrinin in isolated form is administered to the patient about one or two times each day for a first period of time, followed by a second period of time when no Colostrinin is administered.

Claim 29 (previously presented): The method according to claim 28 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.

Claim 30 (previously presented): The method according to claim 28 wherein a cycle of administering Colostrinin in isolated form for a first period of time followed by a second period of time when Colostrinin is administered is repeated at least once.

Claim 31 (previously presented): A pharmaceutical composition for oral administration to a human patient in the treatment of dementia, the pharmaceutical composition comprising a therapeutic unit of Colostrinin in isolated form in combination with a physiologically acceptable carrier.

Claim 32 (previously presented): The pharmaceutical composition according to claim 31 wherein the Colostrinin is non-ovine Colostrinin.

Claims 33-34 (canceled)

Claim 35 (previously presented): The pharmaceutical composition according to claim 31 in the form of a tablet, lozenge or gel.

Claims 36-39 (canceled)

Claim 40 (previously presented): A dietary supplement for humans comprising a therapeutic unit of Colostrinin in isolated form.

Claim 41 (previously presented): A dietary supplement for humans comprising an orally ingestible combination of a therapeutic unit of Colostrinin in an isolated form in combination with a physiologically acceptable carrier.

Claims 42-53 (canceled)

Claim 54 (previously presented): A pharmaceutical composition for oral administration to a human patient comprising a nonapeptide having the amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO:1) in isolated form in combination with a physiologically acceptable carrier.

Claims 55-57 (canceled)

Claim 58 (previously presented): A method of treating a human patient afflicted with Alzheimer's Disease comprising administering a composition comprising a therapeutic unit of Colostrinin in isolated form to the human patient about one or two times per day for a predetermined period of time.

Claim 59 (previously presented): The method according to claim 58 wherein the Colostrinin is non-ovine Colostrinin.

Claim 60 (previously presented): The method according to claim 58, wherein the therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms.

Claim 61 (previously presented): The method according to claim 58 wherein the

therapeutic unit of Colostrinin in isolated form is administered to the patient about one or two times each day for a first period of time, followed by a second period of time when no Colostrinin is administered.

Claim 62 (previously presented): The method according to claim 61 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.

Claim 63 (previously presented): The method according to claim 61 wherein a cycle of administering Colostrinin in isolated form for a first period of time followed by a second period of time when Colostrinin is administered is repeated at least once.

Claim 64 (previously presented): A pharmaceutical composition for oral administration to a human patient in the treatment of Alzheimer's Disease, the pharmaceutical composition comprising a therapeutic unit of Colostrinin in isolated form in combination with a physiologically acceptable carrier.

Claim 65 (previously presented): The pharmaceutical composition according to claim 64 wherein the Colostrinin is non-ovine Colostrinin.

Claim 66 (previously presented): The pharmaceutical composition according to claim 64 in the form of a tablet, lozenge or gel.

Claim 67 (previously presented): A pharmaceutical composition for oral administration to a human patient in the treatment of Alzheimer's Disease, the pharmaceutical composition comprising a therapeutic unit of a nonapeptide having the amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO:1) in isolated form in combination with a physiologically acceptable carrier.

Claim 68 (previously presented): The pharmaceutical composition according to claim 67 in the form of a tablet, lozenge or gel.